Alpha-MSH vs Oxytocin

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

Neuropeptide hormone binding oxytocin receptors throughout brain and body; modulates HPA axis, reduces cortisol, promotes parasympathetic tone

Oxytocin is an endogenous hypothalamic nonapeptide and FDA-approved prescription medication (Pitocin) indicated for initiation and augmentation of labor, management of postpartum uterine atony and hemorrhage, and stimulation of milk letdown in breastfeeding women, acting through peripheral oxytocin receptors in the uterus and mammary gland. Beyond its obstetric and lactation roles, oxytocin functions centrally as a neuromodulator in limbic and cortical circuits involved in social recognition, attachment, trust behavior, and fear regulation, with broadly distributed brain oxytocin receptors mediating effects distinct from its peripheral reproductive actions. A landmark randomized, double-blind trial published in Nature demonstrated that intranasal oxytocin significantly increases trust in humans, and controlled research has subsequently characterized its effects on social attention to facial cues and affective empathy, establishing the central prosocial pharmacology of the peptide in human subjects. Oxytocin is FDA-approved only for its obstetric and lactation indications; intranasal formulations for prosocial, cognitive, or psychiatric applications are investigational, and while the mechanistic rationale is established in healthy-volunteer research, no intranasal oxytocin product has received regulatory approval for any psychiatric or behavioral indication. Intranasal oxytocin in research: studies have administered intranasal oxytocin in doses of 20–40 IU, with 24 IU being the most commonly used dose in human behavioral pharmacology research. This delivery route is studied for the hypothesis that olfactory epithelium absorption provides partial access to the CNS beyond what the blood-brain barrier would permit from systemic routes. Research applications under active investigation include autism spectrum disorder (multiple RCTs examining social cognition outcomes), PTSD (fear extinction augmentation), social anxiety disorder, and borderline personality disorder — none of which has produced a regulatory-ready efficacy signal sufficient for approval as of 2025, though ongoing trial activity is substantial. Oxytocin's anti-inflammatory research profile is also documented — oxytocin receptors are expressed on immune cells and the peptide has been shown to suppress pro-inflammatory cytokine release in preclinical models, an emerging research direction that intersects with gut and systemic inflammation contexts. Telehealth providers and compounding pharmacies offering oxytocin formulations for clinical contexts are listed in the PeptideBase directory.